ESTRO 2024 - Abstract Book

S1789

Clinical - Lung

ESTRO 2024

Keywords: Mesothlioma, radiotherapy, dose escalation

2895

Digital Poster

Bifractionation Radiotherapy and Prophylactic Cranial Irradiation in SCLC: a single-center study

Matteo Sepulcri 1 , Chiara Paronetto 1 , Francesca Gessoni 2 , Alessandro Scaggion 3 , Laura Bonanno 4 , Giorgio Cannone 2 , Marta Paiusco 5 , Valentina Guarneri 4,6 , Federico Rea 7 , Marco Krengli 1,6 1 Veneto Institute of Oncology IOV-IRCCS, Radiotherapy, Padova, Italy. 2 University of Padova, Medicine and Surgery, Padova, Italy. 3 Veneto Institute of Oncology IOV-IRCCS, Medical Physics, Padova, Italy. 4 Veneto Institute of Oncology IOV-IRCCS, Medical Oncology 2, Padova, Italy. 5 Veneto Institute of Oncology IOV-IRCCS, Medical Phyiscs, Padova, Italy. 6 University of Padova, Department of Surgery, Oncology and Gastroenterology, Padova, Italy. 7 University Hospital of Padova, Department of Cardiac, Thoracic, Vascular sciences and Public Health, Padova, Italy

Purpose/Objective:

Small Cell Lung Cancer (SCLC) is a rare neuroendocrine malignancy of the lung.

The majority of patients with SCLC have metastatic disease, while approximately 15% exhibit a more localized disease limited to one lung and the mediastinum, known as "limited stage." Therefore, it is crucial to adjust treatment strategies for these two patient groups.

Radiation therapy is essential in the management of limited stage SCLC, where its efficacy has been firmly established.

The recommended approach for non-metastatic patients with limited stage SCLC involves concurrent chemotherapy (usually cisplatin and etoposide) and radiation therapy. Radiation therapy can be initiated as early as the first or second cycle of chemotherapy, particularly when dealing with extensive disease volumes. Radiation therapy can be delivered once or twice daily, with the latter, known as bi-fractionation (BID), demonstrating its efficacy with the Convert (1) and the CALGB30610/RTOG0538 (2) studies. They affirmed that daily fractionation up to 66Gy / 70Gy could be administered without significant increases in side effects, even though it did not confer superior overall survival outcomes to the twice-daily scheme. So, to this day, the 45 Gy in 30 fractions delivered twice daily remains a favorable approach for patients with limited disease. Nevertheless, its execution could present logistical impediments in terms of scheduling patient appointments and available treatment slots. Our study aims to retrospectively review a series of patients treated by bifractionation radiotherapy including or not PCI.

Material/Methods: